hs-10383
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2022 (NCT05429723)
Timeline
Indications
Studied for
Mechanism of action
- P2X purinoceptor 3ANTAGONIST
P2RX3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06246565 | Phase 2 | Mar 1, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06092983 | Phase 1 | Jun 14, 2023 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT05429723 | Phase 1 | Mar 1, 2022 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Shandong Province Qianfoshan Hospital |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2022 |
| Shandong Province Qianfoshan Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1